Načítá se...
Enhancing venetoclax activity in hematological malignancies
INTRODUCTION: Targeting anti-apoptotic pathways involving the BCL2 family proteins represents a novel treatment strategy in hematologic malignancies. Venetoclax, a selective BCL2 inhibitor, represents the first approved agent of this class, and is currently used in CLL and AML. However, monotherapy...
Uloženo v:
| Vydáno v: | Expert Opin Investig Drugs |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7529910/ https://ncbi.nlm.nih.gov/pubmed/32600066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2020.1789588 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|